CD5 Monoclonal Antibody (UCHT2), eBioscience™, Invitrogen™

Description

• Description: The UCHT2 monoclonal antibody reacts with human CD5, a 67 kDa protein expressed by a majority of thymocytes and mature T cells and a subset of B cells
• Signaling through the CD5 molecule activates T cells and binding of CD5 to its ligand on B cells, CD72, and plays an important role in T-B interaction and proliferation
• The monoclonal antibody UCHT2 recognizes primate CD5
• Applications Reported: The UCHT2 antibody has been reported for use in flow cytometric analysis, immunoblotting (WB), and immunohistochemical staining
• Applications Tested: The UCHT2 antibody has been tested by flow cytometric analysis of normal human peripheral blood cells
• This can be used at less than or equal to 1 μg per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest
• Purity: Greater than 90%, as determined by SDS-PAGE
• Aggregation: Less than 10%, as determined by HPLC
• Filtration: 0.2 μm post-manufacturing filtered
• CD5 is a 67 kDa human T-lymphocyte single-chain transmembrane glycoprotein
• CD5 is present on all mature T-lymphocytes, on most of thymocytes and on many T-cell leukemias and lymphomas
• CD5 also reacts with a subpopulation of activated B-cells and may act as a receptor in regulating T-cell proliferation
• CD5 is found on 95% of thymocytes and 72% of peripheral blood lymphocytes
• In lymph nodes, the main reactivity is observed in T cell areas
• CD5 is expressed by many T cell leukemia, lymphomas, and activated T cells
• Diseases associated with CD5 dysfunction include thymus cancer and Richter's Syndrome.